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Reply to Hamlyn et al.
To the Editor—Hamlyn et al. [1] draw
attention to the limited impact on the
overall number of prevented cases of tu-
berculosis (TB) if a strategy of screening
and treatment of latent TB in HIV-in-
fected patients would be routinely adopted
in a setting of low TB prevalence. Assum-
ing a reduction in the number of TB cases
of 56% by implementation and following
of a screening and preventive treatment
strategy in HIV-infected patients, only 3
TB cases per year would have been pre-
vented in their hospital, where only 5% of
all TB cases occur among patients with
previously diagnosed HIV infection.
Their statement that, in our study, 142
patients had TB before HIV diagnosis is
not entirely correct. These patients had TB
before they gave consent to be observed
in our cohort, but HIV infection may have
been diagnosed earlier. The number of pa-
tients who had TB before or at the time
of diagnosis of HIV infection was 65 [2].
But Hamlyn et al. [1] are correct in point-
ing out that TB diagnosis or clinical signs
of TB are circumstances that lead to the
suspicion and diagnosis of HIV infection
in a considerable proportion of patients
who, therefore, are not eligible for tuber-
culin skin tests (TSTs) and preventive
therapy. Only earlier detection of HIV in-
fection could enable us to prevent TB in
a proportion of this population.
The concern of Hamlyn et al. [1] about
the efficiency of a strategy of TB preven-
tion is in concordance with the editorial
commentary by Rieder [3] that accom-
panied our article. A large part of the
questionable efficiency results from the
difficulties in implementing the TB-pre-
vention strategy, as shown in our cohort,
in which certain centers performed TSTs
for !40% of patients and in which only
37% of patients with positive TST results
received preventive therapy.
Every treatment facility has to decide
whether implementing a TB-prevention
strategy makes sense in their setting. Our
data suggest that preventive chemopro-
phylaxis is efficacious and effective.
Among the individuals with positive TST
results, 15 have to be treated to prevent 1
case of TB, and the corresponding number
to treat for patients who originate from
countries where TB is highly endemic is
estimated to be 8. Therefore, we decided
to enhance the means of detection and
treatment of latent TB in our cohort, be-
cause we believe that this strategy is fea-
sible in our setting.
There are several reasons to justify such
an approach, even if the absolute number
of prevented cases seems to be modest.
First, identification and treatment of in-
dividuals at high risk of developing TB are
crucial public health issues and corner-
stones of TB-control policies. Therefore,
considering the absolute number of pre-
vented diseases in a cohort study of HIV-
individuals does not take into account the
potential number of prevented cases that
would have been infected by those pa-
tients. Second, at an individual level, treat-
ment of active TB carries a higher risk of
nonadherence, adverse effects, and drug
interactions with antiretrovirals than does
preventive treatment [4, 5]. In addition,
the risk of immune reconstitution syn-
drome in HIV-infected individuals after
receipt of TB and antiretroviral treatment
may lead to considerable morbidity and
favors TB-prevention strategies [6–8].
Finally, we do not believe that IFN-g
release assays will accurately identify all
HIV-infected patients with latent TB be-
cause of the reduced sensitivity among im-
munodeficient patients [9]. However, we
can expect a higher specificity, leading to
a reduced number of patients in need of
preventive therapy—especially among
persons who have been vaccinated with
bacille Calmette-Gue´rin [10].
Therefore, we think that screening HIV-
infected patients for latent TB with TSTs
or, possibly, IFN-g release assays and treat-
ing those patients with suspected latent TB
is an advisable strategy to reduce TB-re-
lated morbidity, even in the setting of a
low TB prevalence.
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